Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Vaccine coverage, antibodies against measles, mumps, rubella, hepatitis B in inflammatory bowel disease and juvenile idiopathic arthritis children
Elizaveta Makarova, Olga Goleva, Tatiana Gabrusskaya, Natalia Lubimova, Natalia Ulanova, Natalia Volkova, Elena Shilova, Maria Revnova, Susanna Kharit, Mikhail Kostik
Elizaveta Makarova, Maria Revnova, Department of Polyclinic Pediatrics, Saint-Petersburg State Pediatric Medical University, Saint-Petersburg 194100, Russia
Olga Goleva, Department of Experimental Medical Virology, Molecular Genetics and Biobanking, Federal Research and Clinical Center for Infectious Diseases, Saint Petersburg 197022, Russia
Tatiana Gabrusskaya, Department of Children's Diseases named after Professor I. M. Vorontsov, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Russia
Natalia Lubimova, Department of Pediatric 1, Almazov National Medical Research Centre, Saint Petersburg 197341, Russia
Natalia Ulanova, Natalia Volkova, Elena Shilova, Department of Gastroenterology, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Russia
Susanna Kharit, Research Department of Vaccine Prevention and Post-Vaccination Pathology, Federal Research and Clinical Center for Infectious Diseases, Saint Petersburg 197022, Russia
Susanna Kharit, Department of Infectious Diseases in Children, Faculty of Postgraduate Studies, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Russia
Mikhail Kostik, Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Russia
Author contributions: Makarova E, Kharit S, and Kostik M contributed to conceptualization, writing review, and editing; Kostik M, Makarova E, and Goleva O contributed to design and methodology; Gabrusskaya T, Volkova N, Ulanova N, Shilova E contributed to software, resources, and data curation, validation; Makarova E and Kostik M contributed to formal analysis and interpretation, the literature search and writing original draft; Makarova E and Goleva O contributed to the investigation; Revnova M, Kharit S, and Kostik M contributed to funding, supervision, and project administration; Makarova E, Revnova M, Kharit S, and Kostik M contributed to the critical review of the manuscript; and all authors have read and agreed to the published version of the manuscript.
Institutional review board statement: The study was approved by the Ethics Committee of St. Petersburg State Pediatric Medical University (protocol No. 09/02, dated November 2, 2022).
Clinical trial registration statement: The study was registered at the Research Department of the Saint Petersburg State Pediatric Medical University on May 19, 2021. No URL provided.
Informed consent statement: Written consent from the parents and patients older than 14 years has been obtained in accordance with the Declaration of Helsinki.
Conflict-of-interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Data sharing statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Mikhail Kostik, Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Lytovskaya 2, Saint Petersburg 194100, Russia.
kost-mikhail@yandex.ru
Received: June 24, 2025
Revised: July 10, 2025
Accepted: September 23, 2025
Published online: December 9, 2025
Processing time: 131 Days and 7.1 Hours
BACKGROUND
Children with juvenile idiopathic arthritis (JIA) and inflammatory bowel disease (IBD) face an elevated risk of severe infection owing to their diseases and the immunosuppressive treatment for disease control.
AIM
To compare scheduled vaccination coverage and the levels of post-vaccine antibodies against measles, mumps, rubella (MMR) and hepatitis B in pediatric patients with IBD and JIA.
METHODS
A comparative cohort study included 97 patients with IBD and 170 patients with JIA. Vaccination history was obtained from medical records, while post-vaccination immunity was assessed prospectively by measuring specific IgG antibody titers using enzyme-linked immunosorbent assays (Vector-Best JSC, Russia; IBL International, Germany) during routine visits between January 2022 and April 2023.
RESULTS
A complete two-dose MMR course had been administered to 66.3% of IBD patients and 55.9% of JIA patients (P = 0.121). By contrast, the three-dose hepatitis B schedule was completed in 74.2 % of IBD and 100 % of JIA patients (P < 0.001). Protective level of anti-vaccine antibodies against measles (47.7% vs 57.7%; P = 0.168); mumps (75.3% vs 80.0%; P = 0.366); rubella (74.4% vs 98.2%; P < 0.0001); and hepatitis B (44.8% vs 50.0%; P = 0.514) were detected in IBD and JIA patients, respectively.
CONCLUSION
Patients with IBD and JIA demonstrated different vaccination coverage patterns and levels of anti-vaccine antibodies. Routine baseline serology and timely booster vaccination should be implemented for all pediatric patients receiving chronic immunosuppression.
Core Tip: Vaccination is the primary strategy for preventing infections in children. Patients with juvenile idiopathic arthritis (JIA) and inflammatory bowel disease (IBD) have reduced immunity and increased susceptibility to infections. The immunogenicity of vaccines in children with IBD and JIA remains a topic of controversy. The study compared vaccination coverage and antibody levels against measles, mumps, rubella, and hepatitis B in children with IBD and JIA. Patients with IBD demonstrated lower rates of seropositivity, particularly for rubella and hepatitis B. In contrast, patients with JIA tend to maintain a more stable response to vaccination.
